Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | NQO1 | P15559 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10002471 | 0.91 | CYP3A4 (0.39) | KDM4EKMT2ACYP3A4SMN1; SMN2 | |
| SCHEMBL1515605 | 0.91 | KDM4E (0.36) | KDM4EKMT2ACYP3A4SMN1; SMN2 | |
| SCHEMBL7957356 | 0.89 | SMN1; SMN2 (0.41) | KDM4EKMT2ACYP3A4SMN1; SMN2 | |
| SCHEMBL20472996 | 0.85 | KDM4E (0.33) | KDM4EKMT2A | |
| SCHEMBL21636890 | 0.84 | CYP3A4 (0.33) | KDM4EKMT2ACYP3A4SMN1; SMN2 | |
| SCHEMBL18756141 | 0.82 | DGAT1 (0.43) | KDM4EKMT2ASPHK1 | |
| SCHEMBL10002389 | 0.79 | MAPK1 (0.33) | KDM4EKMT2A | |
| SCHEMBL22167635 | 0.77 | FFAR3 (0.38) | CYP3A4SMN1; SMN2 | |
| SCHEMBL21393710 | 0.75 | KMT2A (0.37) | KDM4EKMT2ANPC1 | |
| SCHEMBL13753969 | 0.75 | SPHK1 (0.45) | KDM4EKMT2ASPHK1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117820226-A | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-117624045-A | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-117603138-A | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-117402114-A | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-111757735-B | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2023-09-22 | — | — | CN | disclosed |
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| WO-2021113679-A1 | DIMERIC COMPOUNDS AS STING AGONISTS | MERSANA THERAPEUTICS, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| WO-2019148044-A1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | EXELIXIS, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
| EP-2729459-B1 | SUBSTITUTED AZAHETEROCYCLES FOR THE TREATMENT OF CANCER | MERCK PATENT GMBH (DE) | 2018-08-22 | — | — | EP | disclosed |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2017-12-14 | — | — | US | disclosed |
| US-9199962-B2 | Substituted azaheterocycles for the treatment of cancer | MERCK PATENT GMBH (DE) | 2015-12-01 | — | — | US | disclosed |
| US-20140221366-A1 | Substituted Azaheterocycles for the Treatment of Cancer | MERCK PATENT GMBH (DE) | 2014-08-07 | — | — | US | disclosed |
| EP-2213661-B1 | c-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2011-07-20 | — | — | EP | disclosed |
| US-7504410-B2 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2009-03-17 | — | — | US | disclosed |
| EP-1510516-A1 | PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2005-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355678-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | KDM4E 312/4885KMT2A 977/4885SPHK1 1186/4885 |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | FLT4, FLT1, MET | KDM4E 312/4885KMT2A 977/4885SPHK1 1186/4885 |
| US-11124482-B2 | C-met modulators and methods of use | FLT4, FLT1, MET | KDM4E 312/4885KMT2A 977/4885SPHK1 1186/4885 |
| US-20140221366-A1 | Substituted Azaheterocycles for the Treatment of Cancer | CCNH, CCNA1, MYC | KDM4E 876/4885KMT2A 627/4885SPHK1 2111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.